Tassos Konstantinou

Tassos joined IP Group in January 2019 and specialises in the life science sector. Prior to joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (ex CRT) where he led the commercialisation of drug discovery programmes to pharma and helped set up new companies. He has experience in technology transfer both in the States and the UK and has also held an investment analyst role with SR One, GSK’s venture capital arm. Tassos did a PhD in molecular oncology at the University of Oxford and a postdoc at the University of Chicago.